This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Cerebrovascular Disease  • Cardiovascular System  • Arrhythmias  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Neurol. 1999;56:1059-1060.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE APPROPRIATE use of heparin continues to be one of the most contentious and controversial issues in the fields of neurology and medicine. The introduction of fractionated low-molecular-weight heparin and heparinoids has further complicated the issue for clinicians. Although these newer compounds have theoretical and practical advantages, most clinicians have had little experience with them, and few data are available to guide rational choice between different pharmaceutical products. Clinicians ask, "Which product should be given to which patients, by what route, with or without an initial bolus, at what dose, monitored how, and when should the treatment be started?"

In this edition of the ARCHIVES, Chamorro et al¹ address the question of when to administer heparin. The great majority of clinicians would agree that the group of patients that they chose to treat with anticoagulants—patients with atrial fibrillation who have an embolic stroke—was appropriate. Many randomized trials have shown that . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Heparin in Acute Stroke With Atrial Fibrillation: Clinical Relevance of Very Early Treatment
Angel Chamorro, Nicolas Vila, Carlos Ascaso, and Rosa Blanc
Arch Neurol. 1999;56(9):1098-1102.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Considering the Role of Heparin and Low-Molecular-Weight Heparins in Acute Ischemic Stroke
Moonis and Fisher
Stroke 2002;33:1927-1933.
ABSTRACT | FULL TEXT  

Secondary Stroke Prevention in Atrial Fibrillation : Lessons From Clinical Practice
Evans et al.
Stroke 2000;31:2106-2111.
ABSTRACT | FULL TEXT  

More on Heparin in Stroke
JWatch General 1999;1999:2-2.
FULL TEXT